Keywords: Millennium, Seattle Genetics, Takeda, Collaboration, Antibody-drug conjugate, Brentuximab

Millennium expands antibody-drug conjugate collaboration with Seattle Genetics

Article | 16 March 2011

Print This

The USA’s Seattle Genetics (Nasdaq: SGEN) says that Millennium, a wholly-owned US subsidiary of Japan’s largest ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in